What do clinical data and studies say about Cosentyx in pregnancy?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, lacks large-scale controlled trials in pregnant women due to ethical constraints. Animal studies show no direct harm to fetuses at doses up to 30 times human levels, but human data is limited to registries and case reports. The TREAT registry and other observational data report no clear increase in major birth defects or miscarriages among ~300 exposed pregnancies, with live birth rates around 80-90% similar to the general population.[1][2]
What is the official pregnancy category and labeling?
Cosentyx carries a Pregnancy Category B (old FDA system) from animal data alone, with no adequate human studies. Current labeling states it can cross the placenta, especially in the third trimester, potentially exposing newborns to immunosuppression. The label recommends avoiding use if possible, weighing benefits against risks, and considering alternatives like topical therapies for mild cases.[3]
What do guidelines from rheumatology and dermatology recommend?
ACR and EULAR guidelines conditionally support Cosentyx in pregnancy for active disease unresponsive to safer options (e.g., methotrexate is teratogenic and avoided). Use is often limited to second/third trimesters to minimize fetal exposure. ACOG notes biologics like secukinumab have a relatively favorable profile compared to small-molecule immunosuppressants, but data gaps persist.[4][5] Discontinuation 4-6 weeks before delivery reduces neonatal risks.
What risks have been reported for mother and baby?
No definitive causal links to adverse outcomes, but post-marketing reports include preterm birth (15-20% vs. 10% baseline), low birth weight, and rare infections in exposed infants due to transplacental transfer (detected up to 6 months postpartum). Maternal disease flares off-treatment pose risks like preeclampsia. Long-term child development data is absent.[1][6]
Can you use Cosentyx while breastfeeding?
Trace amounts appear in breast milk, but oral absorption by infants is negligible. Experts, including the MotherToBaby registry, deem it compatible with breastfeeding, with no reported infant harm.[2][7]
When does the Cosentyx patent expire, and what alternatives exist?
Core patents for secukinumab expire in the US around 2032, potentially delaying biosimilars.[8] Pregnancy-safer alternatives include certolizumab (less placental transfer), ustekinumab, or non-biologic options like apremilast. Consult a specialist for personalized switching.
Sources
[1] Arthritis & Rheumatology: Secukinumab Pregnancy Outcomes
[2] MotherToBaby Fact Sheet: Secukinumab
[3] Cosentyx Prescribing Information
[4] ACR Guidelines on Rheumatic Disease in Pregnancy
[5] EULAR Recommendations
[6] FDA Adverse Event Reporting
[7] LactMed: Secukinumab
[8] DrugPatentWatch: Cosentyx Patents